Tocqueville Asset Management L.P. raised its holdings in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 108.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 711,237 shares of the biopharmaceutical company’s stock after acquiring an additional 370,297 shares during the quarter. Tocqueville Asset Management L.P. owned approximately 0.70% of Sangamo Therapeutics worth $12,055,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in shares of Sangamo Therapeutics by 7.7% in the 1st quarter. Principal Financial Group Inc. now owns 54,480 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 3,910 shares during the last quarter. Amalgamated Bank raised its stake in shares of Sangamo Therapeutics by 38.4% in the 2nd quarter. Amalgamated Bank now owns 15,478 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 4,294 shares during the period. Raymond James Financial Services Advisors Inc. raised its stake in shares of Sangamo Therapeutics by 36.1% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 23,570 shares of the biopharmaceutical company’s stock valued at $335,000 after acquiring an additional 6,250 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Sangamo Therapeutics by 92.1% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 89,686 shares of the biopharmaceutical company’s stock valued at $1,274,000 after acquiring an additional 43,000 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Sangamo Therapeutics by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock valued at $11,218,000 after acquiring an additional 234,346 shares during the period. 63.13% of the stock is owned by institutional investors.
In related news, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Monday, September 17th. The shares were sold at an average price of $14.66, for a total transaction of $73,300.00. Following the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at approximately $179,585. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 25,000 shares of company stock worth $334,550 in the last ninety days. 1.20% of the stock is currently owned by insiders.
A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 28th. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Monday, November 19th. ValuEngine raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 16th. JPMorgan Chase & Co. downgraded shares of Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $35.00 to $11.00 in a research note on Wednesday, November 14th. Finally, Guggenheim downgraded shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 target price on the stock. in a research note on Friday, November 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $19.71.
Sangamo Therapeutics stock opened at $11.89 on Friday. Sangamo Therapeutics Inc has a 12-month low of $9.00 and a 12-month high of $27.50. The firm has a market cap of $1.20 billion, a P/E ratio of -16.99 and a beta of 3.10. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The firm had revenue of $23.56 million for the quarter, compared to the consensus estimate of $26.96 million. During the same quarter in the previous year, the firm posted ($0.15) EPS. The firm’s quarterly revenue was up 99.5% on a year-over-year basis. On average, equities analysts expect that Sangamo Therapeutics Inc will post -0.72 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Tocqueville Asset Management L.P. Raises Stake in Sangamo Therapeutics Inc (SGMO)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/12/07/tocqueville-asset-management-l-p-raises-stake-in-sangamo-therapeutics-inc-sgmo.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Read More: Can individual investors take part in an IPO?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.